Portfolio Companies

NTpharma

Nanovaccines and Biopharmaceuticals in Pseudoadenoviral Nanoparticles and Self-assembling Nanostructures

Shareholders in Portfolio Company 
RUSNANO, Prom-Bi (technology developer), private co-investor

Industry Sector 
Medicine and Pharmacology

Production Location 
Pereslavl-Zalessky, Yaroslavl Oblast
Jobs to be created: 150

Investment Started:  2010

Total Budget

1.55  bln rubles
Co-investment by RUSNANO
1.29  bln rubles

GMP production of nanovaccines and biopharmaceuticals containing carbohydrate binders


The project provides for building a facility for production of vaccines and pharmaceuticals in the municipal area of Pereslavl’-Zalessky, 150 kilometers (85 miles) northeast of Moscow.

The project aims at production of new generation vaccines, including a polyvalent human flu vaccine, and pharmaceuticals for detoxification in oncological therapy and for treatment of amyotrophic lateral sclerosis (ALS/Lou Gehrig’s disease).

NTpharma’s technology allows to reduce by half the time required for culturing and production of the vaccine. This advantage is vital when dealing with vaccines for pandemic flu strains spreading rapidly all over the world.

All vaccines and pharmaceuticals are protected intellectual property of NTpharma LLC.

Area of application

  • Medicine

Market

  • Pharmaceutical distribution companies

Competitive advantages

  • Vaccine production speed increased up to 2 times
  • The first vaccine for influenza with intranasal form of administration
  • The absence of virus replication in cells
  • Manufacturing strains on cell culture eliminating side allergic reactions
  • A genetic vaccine with artificially synthesized antigenic structure
  • Forming a stable viral resistance in 2 to 3 weeks
  • A new category of detoxification pharmaceuticals for combined therapy in oncological treatment
  • An original no-analogue pharmaceutical for treatment of amyotrophic lateral sclerosis

All vaccines and pharmaceuticals are protected intellectual property of NTpharma LLC.

AdeVac-Flu™ is a vaccine that protects against the human influenza infection. This vaccine is a solution for intranasal administration, which contains recombinant pseudoadenoviral particles, expressing haemagglutinin genes of the current strains (A/H1N1, A/H3N2 and B) or other strains recommended by the WHO for each epidemical season. The improved quality of the new genetic vaccine AdeVac-Flu™ is a great advantage for its application in medical practice.

AdeLact™ is a gene therapy preparation for detoxification therapy. It relieves toxic conditions arising in oncological practice during chemo and/or radiotherapy. The gene therapy preparation is based on an adenoviral vector that expresses human Lactoferrin gene (Lf). In vitro AdeLact™ transports the human Lf-gene to cells of the permissive 293 culture and subsequently expresses the human recombinant Lf-gene. In vivo AdeLact™ transports the gene of the target protein (human Lf) to the animal’s organism after a single intravenous injection in the dosage ranging from 1,5•1011 to 430•1011 viral particles/m2. This provides its expression that can be measured quantitatively by means of enzyme immunoassay, taking into account the human recombinant Lf-level in the blood serum of animals. The production of the target proteins is in linear correlation to the dose of the injected preparation.

AdeVasc™ is a genetic drug for the treatment of amyotrophic lateral sclerosis (ALS/Lou Gehrig’s Disease). Amyotrophic lateral sclerosis (ALS, also referred to as Lou Gehrig’s disease or motor neuron disease) is a chronic progressive, clinically and genetically heterogenic fatal disease caused by progressive degeneration of motor neurons, located in the brain and in the the spinal cord. AdeVasc™ is an adenoviral vector construction that expresses VEGF (Vascular Endothelial Growth Factor) and Ang (Angiogenin) genes. AdeVasc™ expresses VEGF- and Ang-genes to increase concentration in blood of the factor stimulating the growth of blood vessels, which improves significantly the scenario for the disease progress.